New catheter trial aims to stop AFib recurrence

NCT ID NCT06747091

Recruiting now Disease control Sponsor: Stavros E Mountantonakis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial compares three different catheter ablation strategies for people with persistent atrial fibrillation (AFib), a heart rhythm problem. Sixty adults aged 18-80 will be randomly assigned to one of three approaches using a special catheter that can switch between two energy types. The goal is to see which strategy best prevents AFib from coming back over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: catheter ablation using a lattice-tip catheter that can switch between radiofrequency and pulsed field energy
What this could lead to: If successful, this could identify the best ablation strategy to reduce recurrence of atrial fibrillation, improving long-term heart rhythm control.
What could go wrong: This is a small, early-stage trial (60 participants) comparing different procedures, so results may not apply broadly. Ablation carries risks like bleeding, infection, or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERSISTENT ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERSISTENT ATRIAL FIBRILLATION

Contacts and locations

Locations

Kristie Coleman
RECRUITING

New York, New York, 10075, United States
Long Island Jewish Medical Center
RECRUITING

New Hyde Park, New York, 11040, United States
North Shore University Hospital
RECRUITING

Manhasset, New York, 11030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.